IX-207-887 | CAS#128439-98-5 | antiarthritic agent

MedKoo Cat#: 145169 | Name: IX-207-887

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IX-207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1) from human monocytes and mouse peritoneal macrophages in vitro at concentrations which are achieved therapeutically in human rheumatoid arthritis and in animal models of arthritis. IX 207-887 has the novel property of being an inhibitor of IL-1 release.

Chemical Structure

IX-207-887

CAS#128439-98-5

Theoretical Analysis

MedKoo Cat#: 145169

Name: IX-207-887

CAS#: 128439-98-5

Chemical Formula: C16H12O3S

Exact Mass: 284.0507

Molecular Weight: 284.33

Elemental Analysis: C, 67.59; H, 4.25; O, 16.88; S, 11.28

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

IX-207-887; IX 207-887;

IUPAC/Chemical Name

(E)-2-(10-methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-ylidene)acetic acid

InChi Key

XIKRQPKFOKKGGW-UKTHLTGXSA-N

InChi Code

1S/C16H12O3S/c1-19-14-8-10-4-2-3-5-11(10)13(9-15(17)18)12-6-7-20-16(12)14/h2-9H,1H3,(H,17,18)/b13-9+

SMILES Code

COC1=CC2=CC=CC=C2\C(=C/C(O)=O)C3=C1SC=C3

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 284.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Dougados M, Combe B, Beveridge T, Bourdeix I, Lallemand A, Amor B, Sany J. IX 207-887 in rheumatoid arthritis. A double-blind placebo-controlled study. Arthritis Rheum. 1992 Sep;35(9):999-1006. doi: 10.1002/art.1780350904. PMID: 1418029. 2: Schnyder J, Bollinger P, Payne T. Inhibition of interleukin-1 release by IX 207-887. Agents Actions. 1990 Jun;30(3-4):350-62. doi: 10.1007/BF01966299. PMID: 2386108. 3: Schnyder J, Cooper P, MacKenzie A. Modulation of secretory processes of phagocytes by IX 207-887. Springer Semin Immunopathol. 1993;14(4):345-52. doi: 10.1007/BF00192308. PMID: 8322166. 4: Schnyder J, Bollinger P, Payne TG. Inhibition of monokine release by IX 207-887. Agents Actions. 1990 Jan;29(1-2):108-10. doi: 10.1007/BF01964734. PMID: 2327310. 5: Mackenzie AR, Bollinger P, Cooper PH, Del Pozo E, Elford P, Graeber M, Gubler HU, Leutwiler A, Payne T, Ruch W, et al. Pharmacological effects of a new antiarthritic agent, IX 207-887. Br J Rheumatol. 1991;30 Suppl 2:75-8. PMID: 1899626. 6: Török K, Németh K, Erdö F, Arányi P, Székely JI. Measurement and drug induced modulation of interleukin-1 level during zymosan peritonitis in mice. Inflamm Res. 1995 Jun;44(6):248-52. doi: 10.1007/BF01782977. PMID: 7583520. 7: Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J Pharm Pharmacol. 1996 Jan;48(1):46-52. doi: 10.1111/j.2042-7158.1996.tb05875.x. PMID: 8722494. 8: Schuerer-Maly CC, Emmenegger U, Ott K, Flogerzi B, Halter F. Interleukin-1 and experimental gastric ulcer healing in the rat. J Physiol Pharmacol. 1993 Mar;44(1):23-9. PMID: 8518422. 9: Erdö F, Török K, Arányi P, Székely JI. A new assay for antiphlogistic activity: zymosan-induced mouse ear inflammation. Agents Actions. 1993 Jul;39(3-4):137-42. doi: 10.1007/BF01998966. PMID: 8304241. 10: Erdö F, Török K, Székely JI. Measurement of interleukin-1 liberation in zymosan air-pouch exudate in mice. Agents Actions. 1994 Mar;41(1-2):93-5. doi: 10.1007/BF01986403. PMID: 8079830. 11: Rainsford KD, Ying C, Smith F. Selective effects of some 5-lipoxygenase inhibitors on synovial interleukin-1 (IL-1) production compared with IL-1 synthesis inhibitors. Agents Actions. 1993;39 Spec No:C186-8. doi: 10.1007/BF01972761. PMID: 8273563. 12: Seibel MJ, Brückle W, Respondek M, Beveridge T, Schnyder J, Müller W. Erste klinische Erfahrungen in der Behandlung chronischer Polyarthritiden mit einem neuen Monokin-Release-Inhibitor [Initial clinical experiences in the treatment of chronic polyarthritis with a new monokine release inhibitor]. Z Rheumatol. 1989 May-Jun;48(3):147-51. German. PMID: 2675492.